FRENCH PATIENTS ENROLLED IN THE WAYFIND-R GLOBAL CLINICO-GENOMIC REGISTRY: A DESCRIPTIVE ANALYSIS OF DEMOGRAPHIC, TUMOUR, AND GENOMIC TESTING CHARACTERISTICS AGAINST OTHER PARTICIPATING COUNTRIES
Author(s)
Paula A. Allier Lechuga, Bsc1, Camille Bachot, MSc1, Thomas Stone, MSc2, David Pau, MSc1.
1Roche, Boulogne-Billancourt, France, 2Roche, Welwyn Garden City, United Kingdom.
1Roche, Boulogne-Billancourt, France, 2Roche, Welwyn Garden City, United Kingdom.
OBJECTIVES: To characterize French (FR) patients in the WAYFIND-R registry (NCT04529122) and identify variations in demographic, tumor, genomic testing, and clinical profiles relative to other participating countries (Rest of the World [RoW]).
METHODS: Launched in 2020, WAYFIND-R is an international, prospective registry collecting real-world data from solid tumor patients who underwent next-generation sequencing (NGS). Data structured in the OMOP common data model (demographic, clinical, genomic variables) was summarized using descriptive statistics.
RESULTS: Based on the April 2026 data cut-off, a total of 7,565 patients were enrolled across 135 active sites in 32 countries (FR:n=1,225[16.2%] from 22 centers). French (FR) patients were older (FR:48.1% aged ≥65 vs. RoW:35.7%). Among patients with a known cancer type, distributions differed: prostate cancer was heavily represented in France (FR:14.6% vs. RoW:4.1%), while lung cancer was more prevalent globally (FR:27.4% vs. RoW:36.8%). Breast and gynecological malignancies (ovary and corpus uteri) were also more frequent in the French cohort (FR:20.7% vs. RoW:14.1%). At data cut-off, NGS sample was available for 1098 FR patients (90%) vs. 5098 (80%) RoW. Liquid biopsy predominated in France (FR:61.0% vs. RoW:21.5%), driven almost entirely by whole peripheral blood. In contrast, solid tissue predominated globally (FR:38.8% vs. RoW:77.2%), primarily using formalin-fixed paraffin-embedded tissue (FR:36.6% vs. RoW:74.7%) over fresh frozen tissue (≤2.6% both). Regarding biospecimen origin, FR samples were less frequently derived from primary tumors (FR:33.5% vs. RoW:60.5%) or metastatic lesions (FR:11.3% vs. RoW:23.6%), originating predominantly from peripheral blood (FR:55.2% vs. RoW:15.9%).
CONCLUSIONS: FR patients enrolled in WAYFIND-R differed from RoW in age, tumour type distribution, and genomic testing practices, with a marked predominance of liquid biopsy. These patterns align with France's established position in NGS, liquid biopsy, and precision oncology. As participating French sites operate large NGS panels, findings may not generalize to all French centers.
METHODS: Launched in 2020, WAYFIND-R is an international, prospective registry collecting real-world data from solid tumor patients who underwent next-generation sequencing (NGS). Data structured in the OMOP common data model (demographic, clinical, genomic variables) was summarized using descriptive statistics.
RESULTS: Based on the April 2026 data cut-off, a total of 7,565 patients were enrolled across 135 active sites in 32 countries (FR:n=1,225[16.2%] from 22 centers). French (FR) patients were older (FR:48.1% aged ≥65 vs. RoW:35.7%). Among patients with a known cancer type, distributions differed: prostate cancer was heavily represented in France (FR:14.6% vs. RoW:4.1%), while lung cancer was more prevalent globally (FR:27.4% vs. RoW:36.8%). Breast and gynecological malignancies (ovary and corpus uteri) were also more frequent in the French cohort (FR:20.7% vs. RoW:14.1%). At data cut-off, NGS sample was available for 1098 FR patients (90%) vs. 5098 (80%) RoW. Liquid biopsy predominated in France (FR:61.0% vs. RoW:21.5%), driven almost entirely by whole peripheral blood. In contrast, solid tissue predominated globally (FR:38.8% vs. RoW:77.2%), primarily using formalin-fixed paraffin-embedded tissue (FR:36.6% vs. RoW:74.7%) over fresh frozen tissue (≤2.6% both). Regarding biospecimen origin, FR samples were less frequently derived from primary tumors (FR:33.5% vs. RoW:60.5%) or metastatic lesions (FR:11.3% vs. RoW:23.6%), originating predominantly from peripheral blood (FR:55.2% vs. RoW:15.9%).
CONCLUSIONS: FR patients enrolled in WAYFIND-R differed from RoW in age, tumour type distribution, and genomic testing practices, with a marked predominance of liquid biopsy. These patterns align with France's established position in NGS, liquid biopsy, and precision oncology. As participating French sites operate large NGS panels, findings may not generalize to all French centers.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
SA7
Topic
Real World Data & Information Systems, Study Approaches
Topic Subcategory
Registries
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology, Personalized & Precision Medicine